Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjögren’s disease

Amgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic Sjögren's disease.

• The trial met its primary goal, showing a meaningful reduction in overall systemic disease activity that emerged quickly then held through 48 weeks.
• Safety was broadly consistent with expectations, with mostly mild-to-moderate side effects and low discontinuation rates.
• Detailed results have not yet been presented; Amgen plans to disclose the full dataset at an upcoming medical meeting.
• A second Phase 3 study in a different Sjögren's population is expected to finish in Q4 2026.